Adaptimmune Therapeutics PLC — Investor Relations & Filings
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K | 2025-03-24 | English | |
| 8-K | 2025-03-24 | English | |
| 8-K | 2025-03-20 | English | |
| OWNERSHIP DOCUMENT | 2025-02-20 | English | |
| OWNERSHIP DOCUMENT | 2025-02-20 | English | |
| OWNERSHIP DOCUMENT | 2025-02-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 12820304 | 10-K | 2025-03-24 | English | ||
| 12820305 | 8-K | 2025-03-24 | English | ||
| 12820306 | 8-K | 2025-03-20 | English | ||
| 12820307 | OWNERSHIP DOCUMENT | 2025-02-20 | English | ||
| 12820308 | OWNERSHIP DOCUMENT | 2025-02-20 | English | ||
| 12820309 | OWNERSHIP DOCUMENT | 2025-02-20 | English | ||
| 12820310 | OWNERSHIP DOCUMENT | 2025-02-20 | English | ||
| 12820311 | OWNERSHIP DOCUMENT | 2025-02-20 | English | ||
| 12820312 | OWNERSHIP DOCUMENT | 2025-02-20 | English | ||
| 12820313 | Major Shareholding Notification 2025 | 2025-02-14 | English | ||
| 12820314 | Major Shareholding Notification 2025 | 2025-02-12 | English | ||
| 12820316 | Major Shareholding Notification 2025 | 2025-02-11 | English | ||
| 12820315 | OWNERSHIP DOCUMENT | 2025-01-18 | English | ||
| 12820317 | OWNERSHIP DOCUMENT | 2025-01-18 | English | ||
| 12820318 | OWNERSHIP DOCUMENT | 2025-01-18 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Adaptimmune Therapeutics PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Adaptimmune Therapeutics PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34721/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34721 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34721 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34721 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34721}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Adaptimmune Therapeutics PLC (id: 34721)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.